Literature DB >> 7739252

Short-course immunosuppression after tracheal allotransplantation in dogs.

R Nakanishi1, K Yasumoto, T Shirakusa.   

Abstract

It is desirable to minimize immunosuppression after allotransplantation. We examined the usefulness of a short course of immunosuppression after tracheal allotransplantation in 35 dogs. Five animals with six-ring tracheal autografts served as controls (group I, n = 5). Thirty animals with six-ring tracheal allografts were randomly classified into five groups as follows: no immunosuppression (group II, n = 6), azathioprine for only 1 postoperative week (group III, n = 7), azathioprine for 2 postoperative weeks (group IV, n = 7), azathioprine for 3 postoperative weeks (group V, n = 5), and mizoribine for 3 postoperative weeks (group VI, n = 5). All allografts in groups II through VI sustained rejection, but there was no difference in mononuclear cell infiltration of the grafts among the groups. The only grafts with long-term viability were those in groups I and VI, as demonstrated by graft patency and epithelialization. We conclude that immunosuppression with mizoribine for only a short course after transplantation may allow long-term viability of tracheal allografts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739252     DOI: 10.1016/S0022-5223(95)70316-0

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

Review 1.  [Tissue engineering of respiratory epithelium. Regenerative medicine for reconstructive surgery of the upper airways].

Authors:  M Bücheler; U von Foerster; A Haisch; F Bootz; S Lang; N Rotter
Journal:  HNO       Date:  2008-03       Impact factor: 1.284

2.  Cryopreservation of the tracheal grafts: Review and perspective.

Authors:  Ryoichi Nakanishi
Journal:  Organogenesis       Date:  2009-07       Impact factor: 2.500

3.  Improved airway healing using basic fibroblast growth factor in a canine tracheal autotransplantation model.

Authors:  R Nakanishi; M Hashimoto; K Yasumoto
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.